2004•Journal of the American Academy of DermatologyRequires access

Imiquimod 5% cream for the treatment of actinic keratosis: results from two phase III, randomized, double-blind, parallel group, vehicle-controlled trials

Mark Lebwohl, Scott M. Dinehart, David Whiting, Peter K. Lee, Naji Tawfik, Joseph L. Jorizzo, James H. Lee, Terry L. Fox

Open publisher page 293 citations

Abstract

This record does not include an abstract. Use the full-text link above if available.

About this research paper

What this paper is about

An abstract is not available in the OpenAlex record for this paper.

Why it matters

OpenAlex reports 293 citations for this work. Citation counts describe recorded attention and do not establish research quality.

Key contribution

A contribution statement is not available in the OpenAlex record.

Method / approach

Method details are not available in the OpenAlex metadata.

Main findings

Findings are not separately available in the OpenAlex metadata.

Limitations

Limitations are not available in the OpenAlex metadata.

Applications

Application details are not available in the OpenAlex metadata.

Key concepts: Imiquimod, Medicine, Actinic keratosis, Dermatology, Erythema, Confidence interval, Randomized controlled trial, Keratosis

Back to paper search Browse research topics Original source

Imiquimod 5% cream for the treatment of actinic keratosis: results from two phase III, randomized, double-blind, parallel group, vehicle-controlled trials — Research Paper | ScholarLens